S. Kuom

Small cell lung cancer and other thoracic malignancies

M. Nishimura, Y. Hosomi, M. Shibuya, 2012 .

Treatment with EGFR tyrosine kinase inhibitors beyond progression in long-term responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival.

M. Faehling, S. Kuom, R. Eckert, 2012 .

EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.

G. Ott, M. Faehling, S. Kuom, 2013, Lung cancer.

Benefit of Erlotinib in Patients with Non-Small-Cell Lung Cancer Is Related to Smoking Status, Gender, Skin Rash and Radiological Response but Not to Histology and Treatment Line

K. Stoiber, C. Schumann, M. Faehling, 2010, Oncology.

EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.

G. Ott, M. Faehling, S. Kuom, 2013, Lung cancer.